AfterRIT Plenary Speaker

Sesquile joined AstraZeneca in 2019 and has held various commercial roles. Most recently, Sesquile has been leading the US commercial team focused on innovative IO treatments for gastrointestinal (GI) cancers. He is responsible for a +$1B business portfolio, including in-line and new launches. While at AZ, Sesquile has led Global product and early asset strategies and China/APAC acceleration growth plans in oncology.

Before joining AstraZeneca, Sesquile built an extensive career in US policy, serving in both public and private sectors. He held a public service role at the National Institutes of Health (NIH) and later worked for the Biotechnology Innovation Organization (BIO), where he was Director of Science and Regulatory Affairs. In this capacity, Sesquile led policy formulation, advocacy efforts, and educational initiatives, supporting key priorities for the biopharmaceutical industry. Sesquile was selected as a fellow by the American Association for the Advancement of Science (AAAS), completed his postdoctoral studies at Harvard Medical School, and earned his Ph.D. and a master’s degree in Immunology and Microbiology from the University of Rochester.